<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064272</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000310163</org_study_id>
    <secondary_id>P30CA046592</secondary_id>
    <secondary_id>CCUM-0201</secondary_id>
    <nct_id>NCT00064272</nct_id>
  </id_info>
  <brief_title>UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer</brief_title>
  <acronym>IRB 2003-551</acronym>
  <official_title>Phase II Trial Of Encapsulized Ginger As A Treatment For Chemotherapy-Induced Nausea and Vomiting AKA IRB 2003-213</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: The herb ginger may help to reduce or prevent nausea and vomiting in patients&#xD;
      receiving chemotherapy for cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well ginger works in reducing or&#xD;
      preventing nausea and vomiting in patients who are receiving chemotherapy for cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the prevalence and severity of delayed nausea and vomiting in patients with&#xD;
           cancer undergoing chemotherapy treated with lower-dose ginger vs higher-dose ginger vs&#xD;
           placebo.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the prevalence and severity of acute nausea and vomiting in patients treated&#xD;
           with these regimens.&#xD;
&#xD;
        -  Compare the safety of these regimens in these patients.&#xD;
&#xD;
        -  Determine whether patients can determine if they are receiving placebo or study drug,&#xD;
           and by which variable (e.g., taste, smell, or decrease in nausea and vomiting).&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are randomized to 1 of 3 treatment arms. Patients are stratified according to concurrent&#xD;
      antiemetic type (5-HT_3 antagonist vs NK1 antagonist).&#xD;
&#xD;
        -  Arm I: Patients receive lower-dose oral ginger twice daily.&#xD;
&#xD;
        -  Arm II: Patients receive higher-dose oral ginger twice daily.&#xD;
&#xD;
        -  Arm III: Patients receive oral placebo twice daily. In all arms, treatment begins&#xD;
           immediately after the chemotherapy treatment and continues for 3 days.&#xD;
&#xD;
      Patients are followed at 1 week.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 180 patients (60 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Most efficacious dose</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability to distinguish between receiving placebo or study drug and variables involved (e.g., taste, smell, or decrease in nausea and vomiting)</measure>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Nausea and Vomiting</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive lower-dose oral ginger twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive higher-dose oral ginger twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ginger extract</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of cancer&#xD;
&#xD;
          -  Currently receiving chemotherapy* containing any chemotherapeutic agent at any dose&#xD;
             and experiencing nausea and/or vomiting of any severity (delayed or acute)&#xD;
&#xD;
               -  Chemotherapy regimens may be given orally, IV, or by continuous infusion (single&#xD;
                  day regimens only)&#xD;
&#xD;
          -  Must have received at least 1 prior chemotherapy* course containing any&#xD;
             chemotherapeutic agent and meets the following criteria:&#xD;
&#xD;
               -  Agent is the same that is scheduled for the next round of chemotherapy&#xD;
&#xD;
               -  Experienced nausea and/or vomiting of any severity (delayed or acute)&#xD;
&#xD;
          -  Must be planning to receive a concurrent 5-HT_3 receptor antagonist antiemetic (e.g.,&#xD;
             ondansetron, granisetron, dolasetron mesylate, or palanosetron) or antiemetic&#xD;
             aprepritant (e.g., Emend®) while on chemotherapy&#xD;
&#xD;
          -  No symptomatic brain metastases NOTE: *Chemotherapy may be adjuvant, neoadjuvant,&#xD;
             curative, or palliative&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No history of bleeding disorder&#xD;
&#xD;
          -  No thrombocytopenia&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Able to swallow capsules&#xD;
&#xD;
          -  No gastric ulcer&#xD;
&#xD;
          -  No clinical evidence of current or impending bowel obstruction&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to understand English&#xD;
&#xD;
          -  Able to complete study questionnaires&#xD;
&#xD;
          -  No allergy to ginger&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy regimens with multiple day doses&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy that is classified as high or intermediate risk of causing&#xD;
             vomiting, including radiotherapy to any of the following areas:&#xD;
&#xD;
               -  Total body irradiation&#xD;
&#xD;
               -  Hemi-body&#xD;
&#xD;
               -  Upper abdomen&#xD;
&#xD;
               -  Abdominal-pelvic mantle&#xD;
&#xD;
               -  Cranium (radiosurgery)&#xD;
&#xD;
               -  Craniospinal radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 1 week since prior ginger (teas, capsules, tinctures)&#xD;
&#xD;
          -  No other concurrent ginger (teas, capsules, tinctures)&#xD;
&#xD;
               -  Concurrent foods made with small amounts (no more than ¼ teaspoon) of ginger&#xD;
                  (powdered or fresh) allowed&#xD;
&#xD;
          -  No concurrent therapeutic-doses of warfarin, aspirin, or heparin&#xD;
&#xD;
               -  Concurrent low-dose warfarin to maintain peripheral or central venous access,&#xD;
                  low-dose aspirin (≤ 81 mg), or low-dose heparin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanna Zick, MPH, ND</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Northern Indiana CR Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center CCOP Research Base</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Grand Rapids</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Our Lady of Mercy Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - San Juan</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <keyword>nausea and vomiting</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

